Suppression of Behavioral Activity by Norfenfluramine and Related Drugs in Rats is Not Mediated by Serotonin Release

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1993 Jan 1

PMID 7870948

Citations 4

Authors

C W Callaway

L L Wing

D E Nichols

M A Geyer

Affiliations

Soon will be listed here.

Abstract

Fenfluramine, a phenalkylamine with serotonin (5-HT) releasing properties, decreases motor activity in rats. The following studies assessed the contribution of 5-HT release to the behavioral effects of fenfluramine and norfenfluramine using a behavioral pattern monitor that simultaneously assesses locomotor and investigatory behavior. First, both fenfluramine and its active metabolite d-norfenfluramine dose-dependently reduced locomotor and investigatory activity. The norfenfluramine-induced reduction in activity was not antagonized by pretreatment with the 5-HT uptake inhibitor fluoxetine or the 5-HT synthesis inhibitor p-chlorophenylalanine, drugs that reduce drug-induced 5-HT release. Second, the d- and l-enantiomers of norfenfluramine were nearly equipotent at reducing behavioral activity, although d-norfenfluramine is more potent as a 5-HT releasing agent. Third, p-chloroamphetamine, a drug that shares the 5-HT releasing properties of fenfluramine produced locomotor hyperactivity in the same paradigm. Previous studies indicate that other 5-HT releasing phenalkylamines have behavioral effects resembling those of p-chloroamphetamine rather than those of fenfluramine. Finally, a structurally related drug, 4-methoxy-5-methyl-aminoindan (MMAI), produced dose-dependent reductions in behavioral activity that are similar to the effects of fenfluramine. The behavioral effects of MMAI were not antagonized by fluoxetine or by the 5-HT receptor antagonist methiothepin. These data suggest that the decrease in activity induced by fenfluramine, norfenfluramine and the related drug MMAI is not related to 5-HT release.

Citing Articles

Neonatal +-methamphetamine exposure in rats alters adult locomotor responses to dopamine D1 and D2 agonists and to a glutamate NMDA receptor antagonist, but not to serotonin agonists.

Graham D, Amos-Kroohs R, Braun A, Grace C, Schaefer T, Skelton M Int J Neuropsychopharmacol. 2012; 16(2):377-91.

PMID: 22391043 PMC: 4594858. DOI: 10.1017/S1461145712000144.

Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats.

Vickers S, Benwell K, Porter R, Bickerdike M, Kennett G, Dourish C Br J Pharmacol. 2000; 130(6):1305-14.

PMID: 10903970 PMC: 1572202. DOI: 10.1038/sj.bjp.0703443.

Absence of fenfluramine-induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice.

Lucas J, Yamamoto A, Scearce-Levie K, Saudou F, Hen R J Neurosci. 1998; 18(14):5537-44.

PMID: 9651234 PMC: 6793482.

5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats.

KEHNE J, Padich R, McCloskey T, Taylor V, Schmidt C Psychopharmacology (Berl). 1996; 124(1-2):95-106.

PMID: 8935804 DOI: 10.1007/BF02245609.

References

Garattini S, Buczko W, JORI A, Samanin R . The mechanism of action of fenfluramine. Postgrad Med J. 1975; 51 Suppl 1:27-35. View

Lindquist M, Gotestam K . Open-field behavior after intravenous amphetamine analogues in rats. Psychopharmacology (Berl). 1977; 55(2):129-33. DOI: 10.1007/BF01457847. View

Nash Jr J, Meltzer H, Gudelsky G . Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther. 1988; 245(3):873-9. View

Paulus M, Geyer M . A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants. Psychopharmacology (Berl). 1991; 104(1):6-16. DOI: 10.1007/BF02244547. View

Lorens S, Guldberg H, Hole K, Kohler C, Srebro B . Activity, avoidance learning and regional 5-hydroxytryptamine following intra-brain stem 5,7-dihydroxytryptamine and electrolytic midbrain raphe lesions in the rat. Brain Res. 1976; 108(1):97-113. DOI: 10.1016/0006-8993(76)90167-0. View

Schwartz D, Hernandez L, Hoebel B . Fenfluramine administered systemically or locally increases extracellular serotonin in the lateral hypothalamus as measured by microdialysis. Brain Res. 1989; 482(2):261-70. DOI: 10.1016/0006-8993(89)91189-x. View

Lichtenberg P, Shapira B, Blacker M, Gropp C, Calev A, Lerer B . Effect of fenfluramine on mood: a double-blind placebo-controlled trial. Biol Psychiatry. 1992; 31(4):351-6. DOI: 10.1016/0006-3223(92)90228-r. View

Lorens S . Some behavioral effects of serotonin depletion depend on method: a comparison of 5,7-dihydroxytryptamine, p-chlorophenylalanine, p-choloroamphetamine, and electrolytic raphe lesions. Ann N Y Acad Sci. 1978; 305:532-55. DOI: 10.1111/j.1749-6632.1978.tb31547.x. View

Kostowski W, Gumulka W, Cxlonkowski A . Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenylalanine. Brain Res. 1972; 48:443-6. DOI: 10.1016/0006-8993(72)90208-9. View

10.

Ward N, Ang J, Pavinich G . A comparison of the acute effects of dextroamphetamine and fenfluramine in depression. Biol Psychiatry. 1985; 20(10):1090-7. DOI: 10.1016/0006-3223(85)90007-1. View

11.

Geyer M, Russo P, Segal D, Kuczenski R . Effects of apomorphine and amphetamine on patterns of locomotor and investigatory behavior in rats. Pharmacol Biochem Behav. 1987; 28(3):393-9. DOI: 10.1016/0091-3057(87)90460-6. View

12.

Adell A, Sarna G, Hutson P, Curzon G . An in vivo dialysis and behavioural study of the release of 5-HT by p-chloroamphetamine in reserpine-treated rats. Br J Pharmacol. 1989; 97(1):206-12. PMC: 1854477. DOI: 10.1111/j.1476-5381.1989.tb11943.x. View

13.

McGinty D, Harper R . Dorsal raphe neurons: depression of firing during sleep in cats. Brain Res. 1976; 101(3):569-75. DOI: 10.1016/0006-8993(76)90480-7. View

14.

Callaway C, Wing L, Geyer M . Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther. 1990; 254(2):456-64. View

15.

McKenna D, Guan X, Shulgin A . 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine. Pharmacol Biochem Behav. 1991; 38(3):505-12. DOI: 10.1016/0091-3057(91)90005-m. View

16.

Nichols D, Oberlender R . Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs?. Ann N Y Acad Sci. 1990; 600:613-23; discussion 623-5. DOI: 10.1007/978-1-4613-1485-1_7. View

17.

Fischer J, Cho A . Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther. 1979; 208(2):203-9. View

18.

KEHNE J, McCloskey T, Taylor V, Black C, Fadayel G, Schmidt C . Effects of the serotonin releasers 3,4-methylenedioxymethamphetamine (MDMA), 4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle reflexes in rats. J Pharmacol Exp Ther. 1992; 260(1):78-89. View

19.

Trulson M, Jacobs B . Behavioral evidence for the rapid release of CNS serotonin by PCA and fenfluramine. Eur J Pharmacol. 1976; 36(1):149-54. DOI: 10.1016/0014-2999(76)90266-1. View

20.

Mennini T, Garattini S, Caccia S . Anorectic effect of fenfluramine isomers and metabolites: relationship between brain levels and in vitro potencies on serotonergic mechanisms. Psychopharmacology (Berl). 1985; 85(1):111-4. DOI: 10.1007/BF00427333. View